Unraveling the underpinnings of immune-related adverse events to immune checkpoint inhibitor therapy.
Dr. Villani will discuss the Massachusetts General Hospital translational research program focusing on defining the clinical, cellular and molecular factors involved in driving immune-related adverse events to immune checkpoint inhibitor therapy.
_______________________________________
Alexandra-Chloé Villani holds the positions of Principal Investigator at the MGH Center for Cancer Research and the Center for Immunology and Inflammatory Diseases, where she is also the Director of the Single Cell Genomics Research Program. She is an Assistant Professor of Medicine at Harvard Medical School and an Associate Member of the Broad Institute.
The Villani Lab aims at achieving a higher resolution definition and functional characterization of cell subsets and rules governing human immune response regulation as a foundation for deciphering how immunity is dysregulated in diseases. They are using single-cell ‘multi-omics’ strategies, unbiased systems immunology approaches, and integrative computational frameworks empowering the study and modeling of the human immune system as a function of “healthy” and inflammatory states, disease progression, and response to treatment. The Villani lab is also actively involved in coordinating the Human Immune Cell Atlas Initiative – through which her team has already discovered 5 new immune cell types in human blood– and is working towards developing a comprehensive human immune lexicon that is key to promoting effective bench-to-bedside translation of findings.
Dr. Villani received a B.Sc. in Physiology and a Ph.D. in Experimental Medicine from McGill University, and completed her postdoctoral training as a Banting Postdoctoral Fellow in the field of systems immunology and single-cell genomics at the Broad Institute. Her research has been published in journals including Science, Nature, Cell, Nature Genetics, Nature Immunology and Nature Biotechnology. She is the recipient of numerous honors, including the MGH Transformative Scholar in Medicine Award, the Damon Runyon-Rachleff Innovation Award, and the NIH Director’s New Innovator Award.
Join here via Zoom
Date:
21 June 2021, 13:00 (Monday, 9th week, Trinity 2021)
Venue:
Please, use the following link to access the event via Zoom. https://zoom.us/j/91009961265
Speaker:
Alexandra-Chloé Villani, PhD (Assistant Professor, Harvard Medical School Director, MGH Center for Immunology & Inflammatory Disease Single Cell Genomics Research Program Principal Investigator, Massachusetts General Hospital Center for Cancer Research Associate Member, Broad Institute of MIT and Harvard)
Organising department:
Department of Oncology
Organiser contact email address:
adminsupport@oncology.ox.ac.uk
Host:
Dr Benjamin Fairfax (MRC Weatherall Institute of Molecular Medicine, University of Oxford)
Part of:
Department of Oncology External Seminar
Booking required?:
Not required
Audience:
Public
Editor:
Carmen Fierro
